Drug Trial Radar · NCT06202261
A Study of TQB2930 for Injection Monotherapy or Combination Therapy in Patients With Recurrent/Metastatic Breast Cancer
Last checked: Nov 19, 2026Latest source record: Mar 12, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
154
Planned (sponsor's estimate)
Start
Apr 13, 2023
Primary completion
Dec 2026
Study completion Oct 2027
Sponsor
- Lead sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jan 11, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a phase Ib/II exploratory study. Phase Ib includes the dose escalation and expansion study of monotherapy, as well as the dose escalation study of combination therapy. After determining the maximum tolerated dose (MTD), a dose expansion study is conducted to observe the safety and efficacy in monotherapy. Phase II study is to further observe the safety and efficacy of TQB2930 combined with albumin-paclitaxel (cohort 3), or chemotherapy selected by investigators (cohort 4).
Conditions
- Metastatic Breast Cancer
- Recurrent Breast Cancer
- Advanced Malignancies
Interventions
TQB2930 for injectionDrug
TQB2930 for injection is a HER2 bispecific antibody.
Paclitaxel for injection (albumin-bound)Drug
It is an anti-microtubule chemotherapy drug
TQB3616 capsuleDrug
TQB3616 capsule is a Cyclin-dependent kinase 4/6 (CDK4/6) inhibitor.
Fulvestrant injectionDrug
Fulvestrant is a competitive estrogen receptor antagonist with similar affinity to estradiol
Capecitabine tabletsDrug
Capecitabine is converted to 5-fluorouracil (5-FU) by in vivo enzyme action.
Vinorelbine tartrate injectionDrug
Vinorelbine is an anti-tumor drug of vinca alkaloids.
Eribulin mesylate injectionDrug
Eribulin induces G2/M phase cell cycle arrest, mitotic spindle division, and ultimately apoptosis after prolonged mitotic arrest through its tubulin-based anti-mitotic mechanism.
gemcitabine hydrochloride for injectionDrug
Gemcitabine is a cell cycle specific anti-metabolic anticancer agent
Primary outcomes
What the sponsor says the trial is designed to measure.
- Maximum tolerated dose (MTD)Time frame: Baseline up to 4 months
- Phase II recommended dose (P2RD)Time frame: Baseline up to 1 year
- Investigators assessed Objective remission rate (ORR) based on Response Evaluation Criteria In Solid Tumors (RECIST) 1.1Time frame: Baseline up to 2 year
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Affiliated Cancer Hospital of Chongqing University
Chongqing, Chongqing Municipality, China · Recruiting
Affiliated cancer hospital of harbin medical university
Harbin, Heilongjiang, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.